PROCEPT BioRobotics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System,...
Latest News
12 days ago · marketbeat.com
PROCEPT BioRobotics Q3 Earnings Call HighlightsPROCEPT BioRobotics NASDAQ: PRCT reported 18% revenue growth in the third quarter of 2026 as demand for its HYDROS systems and procedure-related products helped offset slower-than-expected placements at new U.S. accounts.
12 days ago · seekingalpha.com
PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call TranscriptPROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript
12 days ago · zacks.com
PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Lags Revenue EstimatesPROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.38 per share a year ago.
20 days ago · zacks.com
PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?PROCEPT BIOROBO (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
25 days ago · seekingalpha.com
PROCEPT BioRobotics: Compelling Bet On Aquablation's GrowthPROCEPT BioRobotics offers Aquablation to help with symptom relief while preserving sexual and urinary functions for patients. PRCT has ongoing HYDROS placements that further expand its commercial potential. That should eventually require replacements and help equipment revenues. In that sense, PRCT's recurring sales with consumables could become increasingly valuable. However, that assumes that procedure growth continues as well.
28 days ago · gurufocus.com
PROCEPT BioRobotics Corp (PRCT) Shares Surge 4.0% -- What GF Score of 71 Tells InvestorsOn October 19, 2026, PROCEPT BioRobotics Corp (PRCT) shares rose 4.0% to a current price of $18.28. This price is within a 52-week range of $16.67 to $38.11, re
1 month ago · globenewswire.com
PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
2 months ago · globenewswire.com
LAWSUIT ALERT: Investors who lost money with PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares should contact the Shareholders FoundationA lawsuit was filed for certain investors in PROCEPT BioRobotics Corporation shares. NASDAQ: PRCT investors should contact the Shareholders Foundation
2 months ago · prnewswire.com
LAWSUIT NOTICE: NASDAQ: PRCT Investors who lost money with PROCEPT BioRobotics Corporation shares should contact the Shareholders FoundationSAN DIEGO, Sept. 15, 2026 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of PROCEPT BioRobotics Corporation (NASDAQ: PRCT).
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove PRCT